NicOx suspends naproxcinod development as Duchenne hopes rest on partner
This article was originally published in Scrip
Executive Summary
French ophthalmology company NicOx has suspended all development of its compound naproxcinod and is instead pursuing a new partner for the drug – which the company has been trying to get on the market since 1996.